国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (1): 39-42.doi: 10.3760/cma.j.issn.1673-422X.2020.01.007

• 综述 • 上一篇    下一篇

PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值

张李卓1,2, 钱杨洋2, 郑国湾2, 葛明华2()   

  1. 1 浙江中医药大学第二临床医学院,杭州 310053
    2 浙江省人民医院头颈甲状腺外科,杭州 310014
  • 收稿日期:2019-11-20 修回日期:2019-12-01 出版日期:2020-01-08 发布日期:2020-03-22
  • 通讯作者: 葛明华 E-mail:gemingh@163.com

Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer

Zhang Lizhuo1,2, Qian Yangyang2, Zheng Guowan2, Ge Minghua2()   

  1. 1 Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
    2 Department of Head and Neck Thyroid Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
  • Received:2019-11-20 Revised:2019-12-01 Online:2020-01-08 Published:2020-03-22
  • Contact: Ge Minghua E-mail:gemingh@163.com

摘要:

程序性死亡受体1(PD-1)和程序性死亡受体配体1(PD-L1)参与免疫检查点调节,与肿瘤的发生和发展密切相关。在甲状腺癌中,PD-L1的表达及PD-1阳性T细胞的增多可能预示着更高的侵袭性与更大的复发风险。抗PD-1/PD-L1治疗在许多肿瘤中已有显著疗效,但在甲状腺癌方面的疗效还比较局限,需要寻找能够更好预测疗效的生物标志物。进一步了解PD-1/PD-L1的作用机制及其在甲状腺癌中的诊治价值以及与其疗效相关的生物标志物,可为甲状腺癌患者提供新的治疗方法与思路。

关键词: 甲状腺肿瘤, 免疫疗法, PD-1/PD-L1

Abstract:

Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are involved in the regulation of immune checkpoints and are closely related to the occurrence and development of tumors. In thyroid cancer, an increase in PD-L1 expression and an increase in PD-1 positive T cells may be predictive of higher invasiveness and a greater risk of recurrence. Anti-PD-1/PD-L1 therapy has had significant effects in many tumors, but the efficacy in thyroid cancer is still relatively limited, which also requires finding biomarkers those can better predict the efficacy. Further understanding of the mechanism of PD-1/PD-L1, the current research status in thyroid cancer, and biomarkers related to its efficacy may provide new treatment methods and ideas for patients with thyroid cancer.

Key words: Thyroid neoplasms, Immunotherapy, PD-1/PD-L1